ReviewFrontiers in cardiovascular medicine2026
Multimodality cardiovascular imaging in arrhythmic mitral valve prolapse: a state-of-the-art review from structural assessment to myocardial tissue characterization.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitral valve prolapse (MVP) is a prevalent and traditionally benign heart valve disease; however, mounting evidence identifies a subset of patients at risk for malignant ventricular arrhythmias and sudden cardiac death. This narrative review critically examines the role of multimodality imaging in arrhythmic MVP, with an integrative overview of transthoracic echocardiography, cardiac magnetic resonance (CMR), computed tomography, and positron emission tomography. Particular attention is given to the complementary contribution of these modalities to structural, functional, and myocardial tissue characterization, while acknowledging their different levels of evidence and current clinical applicability. The specific added value of this review lies in organizing these imaging findings within a pathophysiological framework that links valve morphology and annular biomechanics to myocardial injury, diffuse fibrotic remodeling, focal replacement fibrosis, and arrhythmic vulnerability, rather than presenting each modality as an isolated diagnostic tool. Advanced CMR techniques, including native T1 and T2 mapping and extracellular volume quantification, are discussed as promising tools for detecting diffuse fibrosis and myocardial tissue characterization that may contribute to early myocardial remodeling. Genetic susceptibility is also considered as a potential modifier of phenotypic heterogeneity rather than as a routine component of current risk stratification. Overall, the reviewed literature supports an evolving framework for phenotypic characterization and mechanistic interpretation in arrhythmic MVP, while highlighting the need for further standardization, prospective validation, and cautious integration of advanced imaging biomarkers into clinical pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.